

HNRPL Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP2950c

Product Information

Application	WB, IHC-P, FC, E
Primary Accession	<u>P14866</u>
Other Accession	<u>Q8R081</u>
Reactivity	Human
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB20811
Calculated MW	64133
Antigen Region	249-277

Additional Information

Gene ID	3191
Other Names	Heterogeneous nuclear ribonucleoprotein L, hnRNP L, HNRNPL, HNRPL
Target/Specificity	This HNRPL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 249-277 amino acids from the Central region of human HNRPL.
Dilution	WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	HNRPL Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	HNRNPL
Synonyms	HNRPL

Function	Splicing factor binding to exonic or intronic sites and acting as either an activator or repressor of exon inclusion. Exhibits a binding preference for CA-rich elements (PubMed: <u>11809897</u> , PubMed: <u>22570490</u> , PubMed: <u>24164894</u> , PubMed: <u>25623890</u> , PubMed: <u>26051023</u>). Component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes and associated with most nascent transcripts (PubMed: <u>2687284</u>). Associates, together with APEX1, to the negative calcium responsive element (nCaRE) B2 of the APEX2 promoter (PubMed: <u>11809897</u>). As part of a ribonucleoprotein complex composed at least of ZNF827, HNRNPK and the circular RNA circZNF827 that nucleates the complex on chromatin, may negatively regulate the transcription of genes involved in neuronal differentiation (PubMed: <u>33174841</u>). Regulates alternative splicing of a core group of genes involved in neuronal differentiation, likely by mediating H3K36me3-coupled transcription elongation and co-transcriptional RNA processing via interaction with CHD8.
Cellular Location	Nucleus, nucleoplasm. Cytoplasm. Note=Localized in cytoplasmic mRNP granules containing untranslated mRNAs. These granules are not identical with P bodies or stress granules


Background

HNRPL is a component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes which provide the substrate for the processing events that pre-mRNAs undergo before becoming functional, translatable mRNAs in the cytoplasm. L is associated with most nascent transcripts including those of the landmark giant loops of amphibian lampbrush chromosomes.

References


Hahm,B., et.al., FEBS Lett. 425 (3), 401-406 (1998) Funke,B., et.al., Nucleic Acids Res. 24 (19), 3821-3828 (1996)


Images




Western blot analysis of HNRPL Antibody (Center) (Cat. #AP2950c) in HepG2, Jurkat cell line lysates (35ug/lane). HNRPL (arrow) was detected using the purified Pab.

Western blot analysis of HNRPL (arrow) using rabbit polyclonal HNRPL Antibody (Center) (Cat. #AP2950c). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the HNRPL gene (Lane 2).





Formalin-fixed and paraffin-embedded human hepatocarcinoma reacted with HNRPL Antibody (Center), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.



HNRPL Antibody (Center) (Cat. #AP2950c) flow cytometric analysis of Jurkat cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.